
Medtronic (MDT) Stock Forecast & Price Target
Medtronic (MDT) Analyst Ratings
Bulls say
Medtronic is positioned for sustained outperformance because its Affera/Sphere-9 pulsed-field ablation platform is driving rapid Cardiac Ablation Solutions growth, with 88% worldwide growth in F1Q27 and management expecting the business to grow 2.5x the broader EP market in FY27. The bullish case is also supported by a broadened growth portfolio that includes Hugo robotics, Symplicity Spyral, and Altaviva, all of which expand addressable markets while helping offset softer areas and reinforcing mid-single-digit top-line growth and margin leverage. Financially, FY27 guidance implies about 7.25% to 7.75% organic revenue growth, adjusted EPS of $5.94 to $6.00, and gross-margin upside from a richer product mix, tariff refunds, and the eventual Diabetes separation.
Bears say
Medtronic is facing a cautious fundamental setup because FY27 guidance implies only 110 bps of organic revenue deceleration, from 6.5% in F1H27 to 5.4% in F2H27, while F2Q27 EPS is guided to $1.32-$1.34, down 2.2% Y/Y. The outlook is further pressured by about $200M of net tariff expense, a 50 bps drag to the FY27 gross margin estimate of 65.0% and a $0.13 headwind to adjusted EPS of $5.97, with future refunds not included in guidance. Beyond tariffs, the bear case centers on slower product growth, competitive encroachment, regulatory and reimbursement risk, and continuing weakness in Structural Heart and Neuromodulation that could keep margins under pressure.
This aggregate rating is based on analysts' research of Medtronic and is not a guaranteed prediction by Public.com or investment advice.
Medtronic (MDT) Analyst Forecast & Price Prediction
Start investing in Medtronic (MDT)
Order type
Buy in
Order amount
Est. shares
0 shares